The effects ofDaying tablet add-on risperidone on the quality of life of the patients with Schizophrenia

Yan Chen,Wei Xiang,Liping Zhu,Jianming Zhang,Weihong Lu,Bin Long,Ying Lu,Haisu Wu,Zhushu Qian,Min Zhao

DOI: https://doi.org/10.3760/cma.j.issn.1673-4246.2016.11.009

2016-01-01

Abstract:ObjectiveTo explore theDaying tablet on the quality of life of the patients with Schizophrenia. MethodsA total of 120 patients with Schizophrenia were randomly divided into two groups, theDaying tablet group (n=58) and the placebo group (n=62). All the patients were given the risperidone as the basic treatment, and theDaying tablet group were given theDaying tablets, but the control group placebo. All the patients were treated for 12 weeks. Clinical effects were evaluated with traditional Chinese medicine symptom scale. The the Mos 36-item Short Form Health Survey (SF-36) were measured at the baseline and 12th week after treatment to evaluate the quality of life. Results By the end of 12 weeks,the difference of two groups was significant in traditional Chinese medicine symptom scale (P<0.05). There were significant difference in the scores of SF-36 (68.39± 10.21vs. 62.70± 15.89,t=2.843), health transitions (2.36± 0.77vs. 2.75 ± 0.75,t=-2.138), physical component summary (74.86 ± 15.89vs. 74.00 ± 15.34,t=2.197), mental component summary (66.35 ± 16.79 vs.60.86 ± 15.17, t=2.6) after treatment between theDaying tablet group and the placebo group (P<0.01 orP<0.05).Conclusions TheDaying tablet combined with risperidone could benefit Schizophrenia patients and improve their quality of life.